Viridian Therapeutics secures up to $600M via royalty sale and debt facility

Viridian Therapeutics, Inc.\DE

DRI Healthcare pays $55M upfront for U.S. revenue rights; up to $300M total tied to VRDN-003 milestones and FDA approval.
Tiered royalties on veligrotug/VRDN-003 net sales: 7.5% up to $600M, then declining to zero above $2B.
Hercules Capital provides $300M term loan facility; $50M drawn at close, with tranches up to $300M depending on milestones.
Loan bears interest at prime+1.45% (floor 8.95%, cap 9.45%), maturity 2030, interest-only through 2029/2030.
Combined financing strengthens balance sheet for pivotal clinical trials and pre-commercial activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.